1,1-Difluoro-5-azaspiro[2.4]heptane hydrochloride, 95.0%, 10g

Linsitinib, 1g

1-Boc-3-Methanesulfonyloxypyrrolidine, 95.0%, 5g

5-Bromo-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid, 95+%, 100mg

2-((TERT-BUTOXYCARBONYL)AMINO)-2-(1-METHYL-1H-PYRAZOL-4-YL)ACETIC ACID, 95.0%, 250mg

4-Methylnicotinamide, 95.0%, 100mg

1-(3H-Benzoimidazol-5-yl)-2-bromo-ethanone, 95.0%, 1g

8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione, 98%, 5g

2-Fluoro-5-sulfino-benzoic acid, 95.0%, 1g

1-(tert-Butoxycarbonyl)-3,3-dimethyl-4-oxopiperidine, 95.0%, 5g

(S)-3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-bromophenyl)propanoic acid, 98%, 1g

GC capillary column ROTI®Cap-1701 MS, 30 m, 0.32 mm, 0.50 µm, 1 Piece(s)

ETHYL 4,5,6-TRICHLORONICOTINATE, 95.0%, 2g